Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Core Insights - Iterum Therapeutics plc is set to release its first quarter 2025 financial results on May 13, 2025, before the U.S. financial markets open [1] - The company will host a conference call at 8:30 a.m. ET on the same day to discuss financial results and business updates [1] Company Overview - Iterum Therapeutics plc focuses on developing next-generation oral and IV antibiotics to combat multi-drug resistant pathogens in both community and hospital settings [3] - The company is advancing its first compound, sulopenem, which has shown potent in vitro activity against various resistant bacteria [3] - Iterum has received FDA approval for ORLYNVAH™ (oral sulopenem) for treating uncomplicated urinary tract infections in adult women with limited treatment options [3] - The company has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem across seven indications [3]